Published on [Permalink]
Reading time: 2 minutes
Posted in:

FT links, (geo)political

While US groups have poured resources into gene therapy, many have been held back by soaring costs and regulatory hurdles in their home market. In China, by contrast, regulators have supported the field by allowing earlier human trials and more flexibility in how they are designed. […] But while Chinese regulators have nurtured innovation, low domestic drug prices have forced companies to look abroad to recoup investment. “One huge disappointment has been that the commercial sales for China’s drug sector have never bloomed,” said Loncar.

So let me see if I got this right: Americans are paying for health care out of their noses to finance the world’s medical innovation which nowadays mostly comes from China, the citizens of which have among the lowest medical costs in the world. Someone here is being played.

✍️ Reply by email

✴️ Also on Micro.blog